Pain Management
Intersect on FHIR™ delivers a complete pain management clinical decision support module — CDC 2022 guideline-aligned MME calculation, benzodiazepine interaction alerts, risk stratification, and naloxone co-prescribing recommendations — built natively on FHIR R6 and active at the point of prescribing.
Clinical Decision Support
The Intersect pain management module generates structured CDS alerts aligned to the CDC 2022 Clinical Practice Guideline for Prescribing Opioids — surfaced to the prescriber before the order is placed, not after the fact.
CDC recommends avoiding or carefully justifying doses at or above 90 MME/day. The platform calculates total daily MME across all active opioid prescriptions in real time and triggers this alert automatically, with a recommendation to consider tapering to the lowest effective dose.
Concurrent prescribing of benzodiazepines and opioids significantly increases risk of fatal overdose. The platform detects overlapping active prescriptions across both drug classes and flags this combination for immediate clinical review, regardless of which prescriber ordered each medication.
CDC recommends reassessing the risk-benefit balance when approaching 50 MME/day and considering non-opioid or non-pharmacologic alternatives. This alert prompts the prescriber to document clinical justification for continued dosing at this level.
For patients on ≥50 MME/day, concurrent benzodiazepine use, or with a history of substance use disorder, the platform recommends naloxone co-prescribing. The alert checks whether naloxone is already on the active medication list before triggering.
For patients on long-term opioid therapy, the platform tracks the date of the last urine drug screen. If no UDS is on record, or the most recent screen is more than 90 days old, the prescriber is alerted with the number of days elapsed since the last test.
PHQ-9 scores of 10 or above and GAD-7 scores of 10 or above are surfaced as risk factors in the pain management summary. Patients with PHQ-9 ≥20 or GAD-7 ≥15 are flagged as high severity. Suicide risk indicators are also tracked from the active conditions list.
MME Calculation
Total daily MME is calculated automatically across all active opioid prescriptions using CDC 2022 conversion factors — not estimated or approximated. Every prescriber caring for the patient sees the same calculated total.
MME is calculated using the official CDC 2022 opioid conversion factors — not approximations. Oxycodone, hydrocodone, morphine, fentanyl, methadone, and all other scheduled opioids are converted at their published equivalency ratios.
Total MME is calculated across all active prescriptions regardless of which provider wrote each one. A patient receiving opioids from both a pain specialist and a primary care physician will have their combined total surfaced to every prescriber in the platform.
All calculations are derived from structured FHIR R6 MedicationRequest resources — not free-text notes. Dosage, frequency, and route are structured fields, enabling accurate automated calculation without manual data entry.
MME history is tracked over time, enabling the care team to see trends in opioid dosing across a patient's record — not just a point-in-time snapshot. Tapering progress is visible longitudinally.
Pain Management Summary
The Intersect pain management summary organizes the complete clinical picture for a pain management patient into five structured sections — drawing from FHIR resources across the patient record, not from manual data entry.
Active and historical pain-related conditions
Structured scoring and validated instruments
Opioids, non-opioids, and non-pharmacologic care
Stratified by severity — high, moderate, low
Active clinical decision support — CDC 2022 aligned, generated at the point of prescribing
Drug Interactions & Risk Combinations
The platform detects high-risk drug combinations across all active prescriptions, regardless of which provider wrote each order. Cross-prescriber visibility is built into the platform architecture.
| Drug Combination | Risk Level | CDC / FDA Guidance | Platform Action |
|---|---|---|---|
| Opioid + Benzodiazepine | Critical | FDA Black Box Warning — concurrent use substantially increases risk of fatal overdose | Immediate alert to prescriber; both medications flagged in treatment section |
| Opioid ≥90 MME/day | Critical | CDC 2022 — avoid or carefully justify; tapering to lowest effective dose recommended | Critical MME alert with tapering recommendation; longitudinal MME trend visible |
| Opioid + Substance Use Disorder History | Critical | CDC 2022 — high risk for opioid-related harm; naloxone co-prescribing strongly recommended | Risk factor flagged at high severity; naloxone alert triggered automatically |
| Opioid 50–89 MME/day | Warning | CDC 2022 — reassess risk-benefit; consider non-opioid alternatives | Warning alert with non-opioid alternatives prompt; documentation of clinical justification recommended |
| Opioid + Active Depression (PHQ-9 ≥10) | Warning | CDC 2022 — mental health comorbidities increase risk of opioid-related harm | Depression risk factor surfaced at moderate or high severity based on PHQ-9 score |
| Long-term Opioid — No Recent UDS | Monitor | CDC 2022 — periodic urine drug screening recommended for all patients on long-term opioid therapy | UDS overdue alert with days-since-last calculation; prompts ordering of drug screen |
Remote Patient Monitoring
Chronic pain patients require ongoing monitoring between clinical visits. Intersect RPM extends the care team's reach — tracking vital signs, pain levels, and medication adherence continuously, with automated alerts when thresholds are crossed.
Continuous monitoring of vital signs for chronic pain patients, including patients on high-dose opioids where respiratory status and sedation risk require active surveillance.
Patients report pain levels, functional status, and symptom burden between visits via the mobile app — providing the care team with longitudinal pain data rather than a single point-in-time rating at the clinic visit.
For patients on complex pain medication regimens, the mobile app delivers structured reminders and adherence tracking — supporting both therapeutic compliance and safety monitoring.
For rural patients who travel significant distances to pain management specialists, the Intersect telehealth and RPM model brings the specialist visit to the patient — reducing travel burden and improving care continuity.
Whether you are a Critical Access Hospital seeking to improve opioid prescribing safety or an academic medical center looking to standardize pain management CDS across a large network, Intersect on FHIR™ delivers the infrastructure. Let’s talk about your specific environment.
See how Intersect on FHIR™ surfaces CDC-aligned alerts, calculates real-time MME, and keeps every prescriber informed — before the order is placed.
Request a Demo